|
US2021121510A1
|
|
Bacteriophage compositions
|
|
CA3056307A1
|
|
Treatment of idiopathic pulmonary fibrosis
|
|
WO2018069210A1
|
|
Tetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4
|
|
AU2017317575A1
|
|
Treatment of nonalcoholic fatty liver disease
|
|
CN108135886A
|
|
For the PDE4 inhibitor of nephrosis treatment
|
|
WO2016079277A1
|
|
Use of an anti-gm-csf antagonist in the treatment of an infectious disease
|
|
WO2016079276A1
|
|
Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease
|
|
KR20160149210A
|
|
Liquid formulation comprising gm-csf neutralizing compound
|
|
ZA201501316B
|
|
Liquid formulation comprising gm-csf neutralizing compound
|
|
CN106232135A
|
|
Uti fusion protein
|
|
WO2015110394A1
|
|
Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
|
|
CN105705518A
|
|
Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
|
|
WO2015028666A1
|
|
Neutralizing antibody or a fragment thereof specifically binding primate gm-csf for use in the treatment and/or prevention of psoriasis
|
|
TW201540301A
|
|
Treatment of cognitive impairment with PDE4 inhibitor
|
|
CN105189559A
|
|
Formulation of an antibody and use thereof
|
|
EP2914289A1
|
|
Lyophilized formulation comprising gm-csf neutralizing compound
|
|
AU2013234404A1
|
|
Pyrazolone Derivatives as PDE4 Inhibitors
|
|
WO2014012954A1
|
|
Treatment of partly controlled or uncontrolled severe asthma
|
|
CN104507906A
|
|
Novel EP2 receptor agonists
|
|
EP2727602A1
|
|
Method for preparation of a high concentration liquid formulation of an antibody
|
